ARCHIVES

Lilly drug Alimta misses the target, but wins ODAC endorsement for lung cancer. FDA’s Pazdur tells ODAC that decision on Alimta requires clinical judgment.

This article is from The Cancer Letter archive.

Vol. 30 No. 31 | July 30, 2004

Download PDF Visit The Full Archive

Related Articles

House Committee Investigates FDA Commissioner; False and Misleading Testimony Alleged.

April 6, 2007

Samuel Broder Plans To Leave Celera.

September 10, 2010

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

April 13, 2007

In Brief: Robert Day New AACI President, John Potter President Elect: Howard Appointment Near

June 21, 1985

In Brief: Longmire Reappointed to Panel; New Organ System Group For Brain-CNS Tumors Asked

April 26, 1985

MRI Detects Cancer In The Opposite Breast Of Newly Diagnosed Women, Study Finds

March 30, 2007